Showing results (61-70 of 72) with videos related to
Sort By:
Pageof 8
Transfusion|March 25, 2018
Detection, characterization, and enrollment of donors of Ebola convalescent plasma in Sierra LeoneRichard S Tedder, Dhan Samuel, Steve Dicks, et al.Cancer Discovery|April 8, 2015
Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 "Gatekeeper" F691L Mutation with PLX3397Catherine C Smith, Chao Zhang, Kimberly C Lin, et al.Haematologica|December 28, 2023
LNK/SH2B3 as a novel driver in juvenile myelomonocytic leukemiaAstrid Wintering, Anna Hecht, Julia Meyer, et al.Nature Biotechnology|March 6, 2023
Microfluidics-free single-cell genomics with templated emulsificationIain C Clark, Kristina M Fontanez, Robert H Meltzer, et al.Biorxiv : the Preprint Server for Biology|April 1, 2025
In vivo validation of the palmitoylation cycle as a therapeutic target in NRAS-mutant cancerMatthew Decker, Benjamin J Huang, Timothy Ware, et al.Blood|June 1, 2026
Dynamic genetic and nongenetic RAS pathway activation drives resistance to FLT3 and BCL2 inhibitor therapyVanessa E Kennedy, Cheryl A C Peretz, Anushka Walia, et al.Haematologica|November 6, 2025
IDH2 mutation is associated with favorable outcome among older adults with newly diagnosed acute myeloid leukemia treated with hypomethylating agent-based therapyFieke W Hoff, Ying Huang, Rina Li Welkie, et al.Nature Cancer|October 31, 2023
Structural surfaceomics reveals an AML-specific conformation of integrin β2 as a CAR T cellular therapy targetKamal Mandal, Gianina Wicaksono, Clinton Yu, et al.Blood Advances|August 7, 2024
Beat-AML 2024 ELN-refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapyFieke W Hoff, William G Blum, Ying Huang, et al.American Journal of Hematology|July 3, 2026
Signaling Mutations Negate the Favorable Impact of NPM1 Mutations in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With VEN/HMAFieke W Hoff, Joshua F Zeidner, Geeta Torlapati, et al.Pageof 8